Lamivudine, Tenofovir disoproxil and Doravirine

Therapeutic indications

Lamivudine, Tenofovir disoproxil and Doravirine is indicated for:

Human immunodeficiency virus type 1 infection

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Doravirine/lamivudine/tenofovir disoproxil combination is indicated for the treatment of adults infected with human immunodeficiency virus type 1 (HIV-1) without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitors (NNRTI) class, lamivudine, or tenofovir.

Doravirine/lamivudine/tenofovir disoproxil combination is also indicated for the treatment of adolescents aged 12 years and older weighing at least 35 kg who are infected with HIV-1 without past or present evidence of resistance to the NNRTI class, lamivudine, or tenofovir and who have experienced toxicities which preclude the use of other regimens that do not contain tenofovir disoproxil.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

100 mg of doravirine, 300 mg of lamivudine and 245 mg of tenofovir disoproxil once daily

Contraindications

Lamivudine, Tenofovir disoproxil and Doravirine is contraindicated in the following cases:

Patients with estimated CrCl <50 mL/min

at least one of

Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.